Strides Pharma to set up 800-mn capacity vaccine suite in Bengaluru

The vaccine suite will have the capacity to manufacture 500 million doses of liquid vaccine and 300 million doses of Lyophilised vaccines annually.
Eyeing the vaccine opportunity created by the Covid-19 pandemic, Strides Pharma Science is in the process of setting up a vaccine suite in Bengaluru, said a top company official. The vaccine lines are a part of the $40 million investment that the company had committed for its associate Stelis Biopharma.

“Existing vaccine capacities globally are not sufficient to cater to the entire global population and there is going to be high demand,” said R Ananthanarayanan, managing director & chief executive officer of the Bengaluru-headquartered pharma company.

Strides is in discussions with all the global players who are in advanced stages of Covid-19 vaccine trials for manufacturing opportunity, said Ananthanarayanan. “While we will manufacture and supply for the global requirement, we would like to retain the ability to supply in the India market too,” he said.

The vaccine suite will have the capacity to manufacture 500 million doses of liquid vaccine and 300 million doses of Lyophilised vaccines annually.

While the equipment installations at the unit will be completed by December end, the suite will go full stream from January. It will be able to produce different types of vaccines including viral vectors, protein subunits, RNA and DNA based vaccines.

The company is also in the process of getting clinical approval for its antiviral Favipiravir drug, a potential Covid-19 treatment, to be supplied to regulated global markets.

Strides on Thursday posted a 45.75 per cent decline in consolidated net profit at Rs 76.9 crore for the quarter ended September. It had posted a net profit of Rs 141.90 crore for the corresponding period of the previous financial year, it said.

“Q2 FY21 was marked by headwinds from Covid-19 that impacted manufacturing and supply of products from our India sites due to intermittent shutdowns. We faced continued challenges in the market due to reduced footfalls in the market, lower elective surgeries and lower prescription rates. However, we continue to believe in our growth momentum across markets,” said Ananthanarayanan.

Consolidated revenue stood at Rs 806.42 crore in the quarter, a rise of 10 per cent as compared to the previous corresponding quarter.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel